Treatment Resistant Depression – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Treatment Resistant Depression – Pipeline Review, H2 2016’, provides an overview of the Treatment Resistant Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression

The report reviews pipeline therapeutics for Treatment Resistant Depression by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Treatment Resistant Depression therapeutics and enlists all their major and minor projects

The report assesses Treatment Resistant Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Treatment Resistant Depression

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Treatment Resistant Depression

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Treatment Resistant Depression pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Amorsa Therapeutics Inc.

Avanir Pharmaceuticals, Inc.

Axsome Therapeutics Inc

Biohaven Pharmaceutical Holding Company Limited

Eli Lilly and Company

Evotec AG

Johnson & Johnson

Otsuka Holdings Co., Ltd.

Relmada Therapeutics, Inc.

Reviva Pharmaceuticals Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Takeda Pharmaceutical Company Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Treatment Resistant Depression Overview 7

Therapeutics Development 8

Pipeline Products for Treatment Resistant Depression - Overview 8

Pipeline Products for Treatment Resistant Depression - Comparative Analysis 9

Treatment Resistant Depression - Therapeutics under Development by Companies 10

Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes 11

Treatment Resistant Depression - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Treatment Resistant Depression - Products under Development by Companies 15

Treatment Resistant Depression - Products under Investigation by Universities/Institutes 16

Treatment Resistant Depression - Companies Involved in Therapeutics Development 17

Addex Therapeutics Ltd 17

Amorsa Therapeutics Inc. 18

Avanir Pharmaceuticals, Inc. 19

Axsome Therapeutics Inc 20

Biohaven Pharmaceutical Holding Company Limited 21

Eli Lilly and Company 22

Evotec AG 23

Johnson & Johnson 24

Otsuka Holdings Co., Ltd. 25

Relmada Therapeutics, Inc. 26

Reviva Pharmaceuticals Inc. 27

Sumitomo Dainippon Pharma Co., Ltd. 28

Takeda Pharmaceutical Company Limited 29

Treatment Resistant Depression - Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 39

(bupropion hydrochloride + dextromethorphan hydrobromide) - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

(dextromethorphan + quinidine sulfate) - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

AMS-410 FA - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

AMS-520 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

AVP-786 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

CX-157 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

DSP-1200 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

esketamine hydrochloride - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

EVT-100 Series - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

LY-341495 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

REL-1017 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

riluzole - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

TAK-653 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

VU-0431316 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Treatment Resistant Depression - Dormant Projects 69

Treatment Resistant Depression - Discontinued Products 70

Treatment Resistant Depression - Product Development Milestones 71

Featured News & Press Releases 71

Mar 17, 2016: Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression 71

Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 71

Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 72

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

List of Tables

Number of Products under Development for Treatment Resistant Depression, H2 2016 8

Number of Products under Development for Treatment Resistant Depression – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Treatment Resistant Depression – Pipeline by Addex Therapeutics Ltd, H2 2016 17

Treatment Resistant Depression – Pipeline by Amorsa Therapeutics Inc., H2 2016 18

Treatment Resistant Depression – Pipeline by Avanir Pharmaceuticals, Inc., H2 2016 19

Treatment Resistant Depression – Pipeline by Axsome Therapeutics Inc, H2 2016 20

Treatment Resistant Depression – Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016 21

Treatment Resistant Depression – Pipeline by Eli Lilly and Company, H2 2016 22

Treatment Resistant Depression – Pipeline by Evotec AG, H2 2016 23

Treatment Resistant Depression – Pipeline by Johnson & Johnson, H2 2016 24

Treatment Resistant Depression – Pipeline by Otsuka Holdings Co., Ltd., H2 2016 25

Treatment Resistant Depression – Pipeline by Relmada Therapeutics, Inc., H2 2016 26

Treatment Resistant Depression – Pipeline by Reviva Pharmaceuticals Inc., H2 2016 27

Treatment Resistant Depression – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 28

Treatment Resistant Depression – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 29

Assessment by Monotherapy Products, H2 2016 30

Assessment by Combination Products, H2 2016 31

Number of Products by Stage and Target, H2 2016 33

Number of Products by Stage and Mechanism of Action, H2 2016 35

Number of Products by Stage and Route of Administration, H2 2016 37

Number of Products by Stage and Molecule Type, H2 2016 38

Treatment Resistant Depression – Dormant Projects, H2 2016 69

Treatment Resistant Depression – Discontinued Products, H2 2016 70

List of Figures

List of Figures

Number of Products under Development for Treatment Resistant Depression, H2 2016 8

Number of Products under Development for Treatment Resistant Depression – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 30

Assessment by Combination Products, H2 2016 31

Number of Products by Top 10 Targets, H2 2016 32

Number of Products by Stage and Top 10 Targets, H2 2016 32

Number of Products by Top 10 Mechanism of Actions, H2 2016 34

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 34

Number of Products by Routes of Administration, H2 2016 36

Number of Products by Stage and Routes of Administration, H2 2016 36

Number of Products by Stage and Molecule Types, H2 2016 38

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports